The DOI matches its Crossref record; 187 of the 188 references it cites were found in a registry or an index.
Gene Therapy in Retinal Dystrophies
Open accessAbstract
Inherited retinal dystrophies (IRDs) are a group of clinically and genetically heterogeneous degenerative disorders. To date, mutations have been associated with IRDs in over 270 disease genes, but molecular diagnosis still remains elusive in about a third of cases. The methodologic developments in genome sequencing techniques that we have witnessed in this last decade have represented a turning point not only in diagnosis and prognosis but, above all, in the identification of new therapeutic perspectives. The discovery of new disease genes and pathogenetic mechanisms underlying IRDs has laid the groundwork for gene therapy approaches. Several clinical trials are ongoing, and the recent approval of Luxturna, the first gene therapy product for Leber congenital amaurosis, marks the beginning of a new era. Due to its anatomical and functional characteristics, the retina is the organ of choice for gene therapy, although there are quite a few difficulties in the translational approaches from preclinical models to humans. In the first part of this review, an overview of the current knowledge on methodological issues and future perspectives of gene therapy applied to IRDs is discussed; in the second part, the state of the art of clinical trials on the gene therapy approach in IRDs is illustrated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In most clinical retinal gene therapy studies, the vector of choice is the rAAV gene expression vector [14].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
TOLENTINO, M. J., BRUCKER, A. J., FOSNOT, J., YING, G.-S., WU, I.-H., MALIK, G., WAN, S., & REICH, S. J. (2004) · RETINA · doi:10.1097/00006982-200402000-00018 · Cited by 172
RetractedTolentino, M. J., Brucker, A. J., Fosnot, J., Ying, G., Wu, I., Malik, G., Wan, S., & Reich, S. J. (2004) · Retina · doi:10.1097/00006982-200408000-00039 · Cited by 32
RetractedDuplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
RNA interference is mediated by 21- and 22-nucleotide RNAs
Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001) · Genes & Development · doi:10.1101/gad.862301 · Cited by 3,310
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 2×
“Indeed, RPE65-LCA clinical trials were initiated in 2007 by groups from the United Kingdom and the United States [83,160,161] following the encouraging results of animal studies.”
BackgroundKetting, R. F., Fischer, S. E. J., Bernstein, E., Sijen, T., Hannon, G. J., & Plasterk, R. H. A. (2001) · Genes & Development · doi:10.1101/gad.927801 · Cited by 1,852
Yang, H., Wang, H., Shivalila, C. S., Cheng, A. W., Shi, L., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.08.022 · Cited by 1,596
Research works printed but not linked: 2
- Duane, T.D., Tasman, W., and Jaeger, A.E. (1996). Molecular physiology and pathology of the retina. Duane’s Clinical Opthalmology, Lippincott-Raven.
- Garanto, 2016, In Vitro and in Vivo Rescue of Aberrant Splicing in CEP290-Associated LCA by Antisense Oligonucleotide Delivery, Hum. Mol. Genet., 25, 2552
Cited by
Schneider, N., Sundaresan, Y., Gopalakrishnan, P., Beryozkin, A., Hanany, M., Levanon, E. Y., Banin, E., Ben-Aroya, S., & Sharon, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101029 · Cited by 224
Maya-Vetencourt, J. F., Manfredi, G., Mete, M., Colombo, E., Bramini, M., Di Marco, S., Shmal, D., Mantero, G., Dipalo, M., Rocchi, A., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0696-3 · Cited by 211
Barani, M., Nematollahi, M. H., Zaboli, M., Mirzaei, M., Torkzadeh‐Mahani, M., Pardakhty, A., & Asadikaram, G. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.09.026 · Cited by 98
The Role of Inflammation in Retinal Neurodegeneration and Degenerative Diseases
Kaur, G., & Singh, N. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010386 · Cited by 101
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“In most clinical retinal gene therapy studies, the vector of choice is the rAAV gene expression vector [14].”
Background
Metadata
- Authors
- Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M.
- Affiliations
- Fondazione G.B. Bietti (IT)
- Istituto Superiore di Sanità (IT)
- National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
- Corresponding author
- Ziccardi, Lucia
- Cordeddu, Viviana
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-11-14
- Volume
- 20
- Issue
- 22
- Pages
- 5722
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6888000
- OpenAlex
- W2987842697
- Cited by
- 107
- References
- 188
- Citations by year
- 2026: 5 · 2025: 16 · 2024: 11 · 2023: 13 · 2022: 16 · 2021: 25 · 2020: 18 · 2019: 1
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi del Molise (submittedVersion)
- Funders
- Ministero della Salute
- Fondazione Roma
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- gene therapy, inherited retinal disease, Leber congenital amaurosis, Luxturna, disease-associated genes, molecular diagnosis, genome sequencing, clinical trials, translational research, retinal degeneration
- MeSH terms
- Gene Editing, Animals, Disease Models, Animal, Genetic Vectors, Humans, Genetic Therapy, Treatment Outcome, Gene Transfer Techniques, Transgenes, Genetic Predisposition to Disease, Retinal Dystrophies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene Therapy in Retinal Dystrophies. https://app.cochat.ai/papers/10.3390/ijms20225722
- The paper
- Ziccardi, L., Cordeddu, V., Gaddini, L., Matteucci, A., Parravano, M., Malchiodi-Albedi, F., & Varano, M. (2019). Gene Therapy in Retinal Dystrophies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms20225722
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.